Livagen vs PEG-MGF
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- PEG-MGF (Pegylated Mechano Growth Factor) is a modified form of MGF (Mechano Growth Factor) where polyethylene glycol (PEG) chains have been attached to extend its half-life from minutes to days. Native MGF is released locally in muscle in response to mechanical stress and quickly degrades. PEGylation allows systemic administration with sustained circulation, enabling whole-body muscle repair and anabolic signaling rather than the purely local effect of native MGF.
- Half-Life
- Short (minutes); gene-regulatory effects are sustained
- ~3 days (due to PEGylation)
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 200–400 mcg
- Frequency
- Daily for 10–30 days
- 2–3x per week
- Key Benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Extended half-life (~3 days) vs native MGF (minutes)
- Systemic muscle satellite cell activation via subcutaneous injection
- Promotes muscle fiber repair and hypertrophy throughout the body
- Enhanced recovery from intense training or muscle injury
- Synergistic with IGF-1 LR3 and growth hormone peptides
- Useful in sarcopenia, post-injury recovery, and athletic performance
- Single injection provides multi-day anabolic signaling
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Water retention and localized swelling
- Potential hypoglycemia at high doses
- Theoretical cancer growth risk (growth factor)
- Injection site reactions
- +1 more
- Stacks With
- —
- —